Amgen Inc.
- Jurisdiction
United States - LEI
62QBXGPJ34PQ72Z12S66 - ISIN
US0311621009 (AMGN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€312.86 23.6% undervalued - Financial strength (Piotroski F-Value)
-
9
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Read full profile
Fundamentals
- Net revenue
€29.77B - Gross margin
64.5% - EBIT
€6.98B - EBIT margin
23.4% - Net income
€5.65B - Net margin
19.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
- Last dividend amount
-
$2.38 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
75.1%
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Marjorie Greene | September 27, 2025 | $1.00K–$15.00K |
| Daniel Meuser | August 20, 2025 | $1.00K–$15.00K |
| Lisa McClain | August 13, 2025 | $1.00K–$15.00K |
| Cliff Bentz | July 9, 2025 | $1.00K–$15.00K |
| Scott Franklin | July 3, 2025 | $1.00K–$15.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
| Cathie Wood |
|
|
|
Sell |
| Nancy Zevenbergen |
|
|
|
Buy |